FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Sandoz Neulasta Biosimilar Approved

[ Price : $8.95]

FDA approves Sandozs Ziextenzo (pegfilgrastim-bmez), a biosimilar to Amgens Neulasta (pegfilgrastim).

Expanded Field-of-View Laparoscope Cleared

[ Price : $8.95]

FDA clears a 270Surgical Ltd. 510(k) for its SurroundScope System, which the company describes as the first laparoscopic camera sy...

Put Tramadol in High CSA Classification: Public Citizen

[ Price : $8.95]

Public Citizen petitions FDA and the Drug Enforcement Administration to up-classify Tramadol and similar drugs from Schedule 4 to ...

CBER Regulatory Meeting SOPP

[ Price : $8.95]

CBER issues a SOPP on regulatory meetings under some user fee programs.

GSK Asks FDA Review of Zofran Information

[ Price : $8.95]

GlaxoSmithKline asks FDA to look at four categories of information that have been raised in litigation over Zofran pregnancy label...

Vyaire Medical Gains Ventilator Clearance

[ Price : $8.95]

FDA clears a Vyaire Medical 510(k) for the bellavista 1000e ventilator.

Cell/Tissue Product eSubmission Instructions

[ Price : $8.95]

CBER posts Instructions for Using the Electronic Human Cell and Tissue Establishment Registration System (eHCTERS).

8 FDA Info Collections Gain OMB Approval

[ Price : $8.95]

Federal Register notice: FDA posts a list of eight information collections that have been approved by OMB.

CDER Office of New Drugs Reorganization in Phase 2

[ Price : $8.95]

CDER says reorganization of the Office of New Drugs moved into Phase 2 11/4.

Innoveix FDA-483 Released

[ Price : $8.95]

FDA releases an FDA-483 with seven observations issued following an inspection at Innoveix Pharmaceuticals.